Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors
Extragonadal Germ Cell Tumor
Ovarian Cancer
Teratoma
Testicular Germ Cell Tumor

Interventions: Biological: filgrastim
Drug: carboplatin
Drug: etoposide
Drug: ifosfamide
Drug: paclitaxel
Procedure: autologous bone marrow transplantation
Procedure: bone marrow ablation with stem cell support

First Posted Date: 2003-01-27

Last Posted Date: 2017-02-23

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 48

Registration Number: NCT00002931

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2016-12-01

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 69

Registration Number: NCT00032032

Locations: 🇺🇸
McFarland Clinic, PC, Ames, Iowa, United States
🇺🇸
Community Cancer Center of Monroe, Monroe, Michigan, United States
🇺🇸
Mercy Cancer Center at Mercy Medical Center - Des Moines, Des Moines, Iowa, United States

and more 48 locations

Docetaxel Plus Carboplatin in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Conditions: Endometrial Cancer
Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2014-01-06

Lead Sponsor: Herbert Irving Comprehensive Cancer Center

Target Recruit Count: 40

Registration Number: NCT00003560

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, United States

Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Phase 3

Conditions: Lung Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-18

Lead Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Target Recruit Count: 300

Registration Number: NCT00039039

Locations: 🇮🇹
Ospedale San Bortolo, Vicenza, Italy
🇮🇹
Ospedale Mariano Santo, Cosenza, Italy
🇮🇹
Ospedale San Martino, Genoa, Italy

and more 34 locations

Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors

Phase 1

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2013-04-05

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT00024284

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States

and more 4 locations

Radiation Therapy Plus Carboplatin and Lobradimil in Treating Children With Newly Diagnosed Brain Stem Gliomas

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: carboplatin
Drug: cereport
Radiation: radiation therapy

First Posted Date: 2003-01-27

Last Posted Date: 2014-02-21

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 13

Registration Number: NCT00005602

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Albert Einstein Clinical Cancer Center, Bronx, New York, United States

and more 16 locations

Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

Phase 2

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Chronic Myeloproliferative Disorders
Leukemia
Myelodysplastic Syndromes
Nonmalignant Neoplasm
Unspecified Adult Solid Tumor, Protocol Specific
Lymphoma
Myelodysplastic/Myeloproliferative Diseases

Interventions: Biological: anti-thymocyte globulin
Drug: busulfan
Drug: fludarabine phosphate
Drug: carboplatin
Radiation: total-body irradiation
Drug: cyclophosphamide
Drug: melphalan
Drug: etoposide
Drug: thiotepa

First Posted Date: 2003-01-27

Last Posted Date: 2021-08-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 361

Registration Number: NCT00003816

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Surgery in Treating Children With Neuroblastoma

Phase 3

Completed

Conditions: Neuroblastoma

Interventions: Procedure: conventional surgery
Biological: filgrastim
Radiation: radiation therapy
Biological: sargramostim
Drug: carboplatin
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: etoposide
Procedure: adjuvant therapy

First Posted Date: 2003-01-27

Last Posted Date: 2017-03-13

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 968

Registration Number: NCT00003119

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
University of Illinois Medical Center, Chicago, Illinois, United States

and more 231 locations